ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Bank of America Analyst Says

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price raised by Bank of America from $29.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective would suggest a potential upside of 17.97% from the stock’s current price.

A number of other research firms also recently issued reports on ACAD. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday. JPMorgan Chase & Co. increased their target price on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 4th. Canaccord Genuity Group raised their target price on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday. Finally, Citigroup increased their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.59.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.23 during trading on Tuesday, reaching $25.43. 736,217 shares of the stock traded hands, compared to its average volume of 1,683,652. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of 11.55, a P/E/G ratio of 31.79 and a beta of 0.84. The business has a fifty day simple moving average of $21.90 and a two-hundred day simple moving average of $23.43. ACADIA Pharmaceuticals has a 52-week low of $19.69 and a 52-week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm had revenue of $268.10 million during the quarter, compared to analysts’ expectations of $280.25 million. During the same quarter in the prior year, the firm posted $0.11 earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 9.7% on a year-over-year basis. On average, research analysts predict that ACADIA Pharmaceuticals will post 0.37 earnings per share for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 5,401 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider directly owned 24,509 shares in the company, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the sale, the executive vice president directly owned 66,145 shares in the company, valued at $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 13,978 shares of company stock valued at $302,819. 26.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp boosted its holdings in ACADIA Pharmaceuticals by 9.0% during the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock valued at $211,296,000 after acquiring an additional 655,257 shares during the period. First Trust Advisors LP increased its stake in ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after purchasing an additional 1,073,834 shares during the period. Geode Capital Management LLC lifted its position in shares of ACADIA Pharmaceuticals by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock worth $86,539,000 after purchasing an additional 106,807 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ACADIA Pharmaceuticals by 8.0% during the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock worth $70,222,000 after purchasing an additional 234,186 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of ACADIA Pharmaceuticals during the third quarter valued at $50,760,000. 96.71% of the stock is owned by institutional investors.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA received a positive CHMP recommendation for Daybue in Europe, a key regulatory step that could expand the drug’s commercial opportunity if the European Commission grants final approval. Article Title
• Positive Sentiment: Canaccord Genuity lifted its price target on ACADIA Pharmaceuticals and kept a buy rating, signaling stronger analyst confidence in the stock’s upside. Article Title
• Neutral Sentiment: Recent commentary noted ACADIA’s commercial momentum in Nuplazid and Daybue, while highlighting pipeline data for remlifanserin as a potential longer-term catalyst rather than an immediate driver. Article Title
• Neutral Sentiment: Analyst coverage elsewhere flagged that the recent move may be hard to sustain in the near term because of earnings estimate trends, even as trading volume remained elevated. Article Title
• Neutral Sentiment: A roundup of healthcare analyst views included ACADIA Pharmaceuticals among other names, but did not appear to introduce a new company-specific thesis beyond the recent Daybue and analyst updates. Article Title

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.